Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H - Salama, A KS; Li, S L; Macrae, E R (Journal of Clinical Oncology, 2019)
et al.